Luteolin — Benefits Deep Dive

Benefits — scientific infographic poster

Luteolin is a plant flavone — chemically 3',4',5,7-tetrahydroxyflavone — that gives celery, parsley, thyme, sweet peppers, and chamomile part of their color and much of their pharmacology. In the laboratory it is one of the most reliably anti-inflammatory and mast-cell-calming molecules in the plant kingdom, and it has become a focus of research into brain inflammation, allergy, and immune balance. It is important to be honest about where the evidence stands: luteolin's antioxidant and anti-inflammatory mechanisms are well characterized in cells and animals, its allergy and mast-cell effects are strong in preclinical models, but the human clinical trials are still small and preliminary — especially for the brain. The four pages below walk through what is genuinely known, what is promising but unproven, and how to get luteolin from ordinary food.

Deep-Dive Articles

🧠

Brain & Neuroinflammation

The most talked-about — and most preliminary — research area. How luteolin quiets activated microglia and mast cells in the brain, the small open-label autism pilot, senescent-mouse memory studies, and the honest limits of the “brain fog” conversation. Mostly cell and animal work plus a handful of tiny human pilots.

Read the deep dive →
🔥

Antioxidant & Anti-Inflammatory

The mechanistic core. Direct free-radical scavenging by the catechol B-ring, activation of the Nrf2/HO-1 antioxidant defense system, and suppression of the NF-κB inflammatory switch that turns down tumor necrosis factor-α, interleukin-6 (IL-6), iNOS, and cyclooxygenase-2 (COX-2). This is the best-established part of luteolin's biology.

Read the deep dive →
🤧

Allergy & Mast Cells

Why luteolin is studied as a natural mast-cell stabilizer. It blunts FcεRI-triggered degranulation and histamine, tryptase, and prostaglandin release — in one human-cell study more potently than the drug cromolyn. Strong in the lab and in allergy-model animals; human trials remain limited.

Read the deep dive →
🥬

Dietary Sources

Where luteolin actually comes from: celery and celery seed, fresh and dried parsley, thyme and other Mediterranean herbs, sweet peppers, chamomile tea, artichoke, and oregano. Realistic food amounts, why dried herbs concentrate it, and why luteolin is poorly absorbed — the bioavailability problem.

Read the deep dive →

The autism pilot mentioned in the first card (Taliou 2013) enrolled 50 children aged 4 to 10, and 40 finished the 26 weeks. There was no placebo group. The capsule held luteolin together with quercetin and rutin, so luteolin was not tested alone. The authors reported better scores on adaptive-behavior and behavior-checklist measures; 27 of the 50 children had temporary irritability lasting 1 to 8 weeks.

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why One Flavone Touches So Many Systems
  3. Luteolin Paired With Palmitoylethanolamide After COVID-19 Smell Loss
  4. Research Papers: Brain & Neuroinflammation
  5. Research Papers: Antioxidant & Anti-Inflammatory
  6. Research Papers: Allergy & Mast Cells
  7. Research Papers: Dietary Sources & Bioavailability
  8. Research Papers: Cross-Cutting (Reviews & Pharmacology)
  9. External Authoritative Resources
  10. Connections
  11. Featured Videos

Why One Flavone Touches So Many Systems

At first glance it seems too convenient that a single molecule from parsley could be relevant to allergy, brain inflammation, and antioxidant defense all at once. The explanation is not that luteolin is a cure-all — it is that these seemingly different problems share a small number of upstream control points, and luteolin happens to touch those control points.

  1. The NF-κB inflammatory switch. NF-κB is a master transcription factor that turns on the genes for inflammatory messengers — tumor necrosis factor-α, IL-6, interleukin-1 beta (IL-1β), iNOS, cyclooxygenase-2. Luteolin interferes with the kinase cascade that activates NF-κB, so it turns the volume down on inflammation wherever that switch is running hot: in a macrophage, in a brain microglial cell, or in the lining of an inflamed airway. This is the single mechanism that most unifies its effects and is explored on the Antioxidant & Anti-Inflammatory page.
  2. The Nrf2 antioxidant defense system. Rather than only scavenging free radicals directly, luteolin activates Nrf2, the transcription factor that switches on the cell's own protective enzymes (heme oxygenase-1, glutathione-synthesizing enzymes). This gives a longer-lasting, self-renewing antioxidant effect than a molecule that is simply consumed when it neutralizes a radical.
  3. Mast-cell and microglial stabilization. Mast cells (in tissues) and microglia (in the brain) are the two “first-responder” cells that release inflammatory mediators fastest. Luteolin dampens both — blocking the calcium influx and FcεRI signaling that make a mast cell degranulate, and shifting microglia from an inflammatory to a quiescent state. This links the allergy story and the brain story, which are really the same cell biology in two different tissues.

The honest caveat that runs through all four pages is bioavailability. Luteolin is poorly water-soluble and heavily metabolized after you eat it, so the striking concentrations that produce these effects in a cell-culture dish are much higher than what circulates after a normal meal. Cohort studies in people with chronic kidney disease and type 2 diabetes do link higher luteolin intake with lower mortality, but these studies cannot show cause. This gap between dish and dinner plate is the main limit on dramatic claims: the research so far has not shown luteolin working as a standalone treatment. The Sources page covers this directly.

The two cohorts come from the US National Health and Nutrition Examination Survey, and each estimated intake from one 24-hour food recall. Among 2,393 people with chronic kidney disease (Yao 2024), median intake was 0.305 mg a day, and over a median of 93 months each unit of higher intake went with 27% lower all-cause and 34% lower cardiac mortality. Among 2,461 people with type 2 diabetes (Zhang 2023), median intake was 0.355 mg a day, and over a median of 8.4 years each log-unit rise in intake went with 7.0% lower all-cause and 22.6% lower cardiac mortality. These numbers also show why dish and mouse results do not translate directly to meals: the senescent-mouse study (Burton 2016) fed luteolin at 6 g per kg of diet for 4 weeks, far from the fraction of a milligram a day people in these cohorts ate.

Back to Table of Contents

Luteolin Paired With Palmitoylethanolamide After COVID-19 Smell Loss

A 2026 meta-analysis (Shi 2026) pooled 7 randomized trials with 525 people who still had smell loss after COVID-19. Those given palmitoylethanolamide plus luteolin along with smell training scored higher on smell tests than those given smell training alone (standardized mean difference 0.90; 95% confidence interval 0.24 to 1.58). In these trials luteolin was given only in this combination, never alone, so the result cannot be credited to luteolin by itself.

Back to Table of Contents

Research Papers: Brain & Neuroinflammation

  1. Theoharides TC (2009). Luteolin as a therapeutic option for multiple sclerosis. Journal of Neuroinflammation — PubMed PMID: 19825165
  2. Jang S et al. (2008). Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. PNAS — PubMed PMID: 18490655
  3. Dirscherl K et al. (2010). Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. Journal of Neuroinflammation — PubMed PMID: 20074346
  4. Burton MD et al. (2016). Dietary Luteolin Reduces Proinflammatory Microglia in the Brain of Senescent Mice. Rejuvenation Research — PubMed PMID: 26918466
  5. Taliou A et al. (2013). An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clinical Therapeutics — PubMed PMID: 23688534

Back to Table of Contents

Research Papers: Antioxidant & Anti-Inflammatory

  1. Xagorari A et al. (2001). Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. Journal of Pharmacology and Experimental Therapeutics — PubMed PMID: 11123379
  2. Aziz N et al. (2018). Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. Journal of Ethnopharmacology — PubMed PMID: 29801717
  3. Seelinger G et al. (2008). Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Medica — PubMed PMID: 18937165
  4. Lin Y et al. (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Current Cancer Drug Targets — PubMed PMID: 18991571
  5. Tan X et al. (2019). Luteolin Exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 Pathway in Intracerebral Hemorrhage. Frontiers in Pharmacology — PubMed PMID: 32038239

Back to Table of Contents

Research Papers: Allergy & Mast Cells

  1. Tsilioni I, Theoharides T (2024). Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells. International Archives of Allergy and Immunology. — PubMed PMID: 38588651
  2. Kritas SK et al. (2013). Luteolin inhibits mast cell-mediated allergic inflammation. Journal of Biological Regulators and Homeostatic Agents. — PubMed PMID: 24382176
  3. Kimata M et al. (2000). Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clinical & Experimental Allergy. — PubMed PMID: 10718847
  4. Hao Y et al. (2022). Luteolin inhibits FcεRI- and MRGPRX2-mediated mast cell activation by regulating calcium signaling pathways. Phytotherapy Research. — PubMed PMID: 35315143
  5. Kim SH et al. (2018). Luteolin attenuates airway inflammation by inducing the transition of CD4+CD25- to CD4+CD25+ regulatory T cells. European Journal of Pharmacology. — PubMed PMID: 29225189

Back to Table of Contents

Research Papers: Dietary Sources & Bioavailability

  1. Miean KH, Mohamed S (2001). Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. Journal of Agricultural and Food Chemistry. — PubMed PMID: 11410016
  2. Shimoi K et al. (1998). Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Letters. — PubMed PMID: 9827549
  3. López-Lázaro M (2009). Distribution and biological activities of the flavonoid luteolin. Mini-Reviews in Medicinal Chemistry. — PubMed PMID: 19149659
  4. Somerset SM, Johannot L (2008). Dietary flavonoid sources in Australian adults. Nutrition and Cancer. — PubMed PMID: 18584477
  5. Yao X, Zhou Z (2024). Dietary intake of luteolin is negatively associated with all-cause and cardiovascular mortality in chronic kidney disease patients. BMC Public Health. — PubMed PMID: 39080632
  6. Zhang W et al. (2023). Luteolin intake is negatively associated with all-cause and cardiac mortality among patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome. — PubMed PMID: 36966325

Back to Table of Contents

Research Papers: Cross-Cutting (Reviews & Pharmacology)

  1. Nabavi SF et al. (2015). Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Research Bulletin. — PubMed PMID: 26361743
  2. Theoharides TC et al. (2019). Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Review of Clinical Immunology. — PubMed PMID: 30884251
  3. Shi M et al. (2024). Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches. Phytotherapy Research. — PubMed PMID: 38088265
  4. Mahto K et al. (2025). Therapeutic potential of luteolin in neurodegenerative disorders: targeting Nrf2, NFκB, MAPK, and JAK-STAT pathways to combat neuroinflammation and apoptosis. Inflammopharmacology. — PubMed PMID: 40694206
  5. Theoharides TC, Tsilioni I (2018). Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases. Current Topics in Medicinal Chemistry. — PubMed PMID: 30451113
  6. Shi Y et al. (2026). Therapeutic effect of anti-neuroinflammatory supplement combined with olfactory training on post-covid olfactory dysfunction: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology. — PubMed PMID: 41559316

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents